Tryptamine Therapeutics (ASX:TYP) EV-to-EBITDA : -7.55 (As of May. 27, 2024)

Tryptamine Therapeutics EV-to-EBITDA Chart

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial						-	-2.34	-	-0.67	-

Competitive Comparison of Tryptamine Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Tryptamine Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tryptamine Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's EV-to-EBITDA falls into.

Tryptamine Therapeutics EV-to-EBITDA Calculation

Tryptamine Therapeutics's EV-to-EBITDA for today is calculated as:

Tryptamine Therapeutics's current Enterprise Value is A$4.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tryptamine Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tryptamine Therapeutics  (ASX:TYP) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Tryptamine Therapeutics's PE Ratio for today is calculated as:

Tryptamine Therapeutics's share price for today is A$0.0275.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tryptamine Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.037.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Tryptamine Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description